974
Participants
Start Date
June 30, 2020
Primary Completion Date
July 15, 2024
Study Completion Date
July 15, 2024
Tolebrutinib
"Pharmaceutical form: Tablet~Route of administration: Oral"
Teriflunomide
"Pharmaceutical form: Tablet~Route of administration: Oral"
Placebo to match Tolebrutinib
"Pharmaceutical form: Tablet~Route of administration: Oral"
Placebo to match Teriflunomide
"Pharmaceutical form: Tablet~Route of administration: Oral"
Investigational Site Number :1580002, Taipei
Investigational Site Number :1580006, Taoyuang
Investigational Site Number :1580003, Taichung
Investigational Site Number :1580005, Kaohsiung City
Investigational Site Number :1000004, Sofia
Investigational Site Number :1000008, Sofia
Investigational Site Number :1000001, Sofia
Investigational Site Number :1000006, Sofia
Investigational Site Number :1000009, Sofia
Investigational Site Number :1000005, Plovdiv
Investigational Site Number :0400004, Linz
Investigational Site Number :1000002, Pleven
Investigational Site Number :2080001, Esbjerg
Investigational Site Number :2080005, Holstebro
Investigational Site Number :3800007, Orbassano
Investigational Site Number :2330001, Tallinn
Investigational Site Number :7240004, Córdoba
Investigational Site Number :3800014, Genova
Investigational Site Number :2760004, Rostock
Georgetown University Medical Center-Site Number:8400119, Washington D.C.
Investigational Site Number :7240008, Donostia / San Sebastian
Investigational Site Number :3800001, Milan
Investigational Site Number :3800010, Milan
Investigational Site Number :2460002, Turku
Investigational Site Number :2760016, Hamburg
Investigational Site Number :3800011, Bergamo
Investigational Site Number :3800008, Pavia
Wake Forest University Baptist Medical Center-Site Number:8400116, Winston-Salem
Meridian Clinical Research, LLC-Site Number:8400005, Raleigh
Investigational Site Number :7240001, Pozuelo de Alarcón
Investigational Site Number :7240005, Málaga
Investigational Site Number :1580007, Hsinchu
Investigational Site Number :7240006, Murcia
Meridian Clinical Research-Site Number:8400003, Savannah
Investigational Site Number :7920006, Mersin
Investigational Site Number :2460001, Tampere
University of South Florida-Site Number:8400006, Tampa
Beth Israel Deaconess Medical Center-Site Number:8400064, Fort Myers
Investigational Site Number :7920002, Istanbul
Investigational Site Number :7920009, Istanbul
Investigational Site Number :7920007, Istanbul
Investigational Site Number :7920008, Izmir
University of Alabama MS Center-Site Number:8400013, Birmingham
Investigational Site Number :2760019, Düsseldorf
Columbus Neuroscience-Site Number:8400010, Westerville
Investigational Site Number :7240003, Seville
Investigational Site Number :7920001, Kocaeli
Investigational Site Number :8040010, Lutsk
The Ohio State University Wexner Medical Center-Site Number:8400150, Columbus
Optimed Research, LTD-Site Number:8400147, Columbus
Investigational Site Number :7240007, Valencia
Investigational Site Number :2760008, Münster
Michigan Institute For Neurological Disorders-Site Number:8400058, Farmington Hills
The Memorial Hospital-Site Number:8400033, Owosso
Investigational Site Number :2030004, Hradec Králové
Investigational Site Number :3800012, Florence
Investigational Site Number :4400003, Kaunas
Investigational Site Number :2330002, Tartu
Investigational Site Number :2030009, Pardubice
Consultants In Neurology-Site Number:8400011, Northbrook
Investigational Site Number :8040016, Kharkiv
Investigational Site Number :8040013, Kharkiv
Missouri Baptist Medical Center-Site Number:8400019, St Louis
Investigational Site Number :8040009, Odesa
Sharlin Health & Neurology-Site Number:8400093, Ozark
Investigational Site Number :8040008, Kherson
Oklahoma Medical Research Foundation-Site Number:8400018, Oklahoma City
University of Texas Southwestern Medical Center-Site Number:8400077, Dallas
Investigational Site Number :2030007, Zlín
Investigational Site Number :8040011, Ivano-Frankivsk
Investigational Site Number :8040001, Lviv
University of Colorado-Site Number:8400012, Aurora
Investigational Site Number :3800003, Napoli
Investigational Site Number :3800006, Napoli
Investigational Site Number :3800002, Pozzilli
Investigational Site Number :2760011, Ulm
Investigational Site Number :4840003, Veracruz
Investigational Site Number :4400002, Klaipėda
University of San Francisco, Sandler Neurosciences Center-Site Number:8400137, San Francisco
Investigational Site Number :3800015, Catania
Providence Multiple Sclerosis Center-Site Number:8400020, Portland
Multiple Sclerosis Center, Swedish Neuroscience Institute-Site Number:8400121, Seattle
Investigational Site Number :1560006, Beijing
Investigational Site Number :1560010, Beijing
Investigational Site Number :1560012, Beijing
Investigational Site Number :1560023, Beijing
Investigational Site Number :1560001, Beijing
Investigational Site Number :1560009, Beijing
Investigational Site Number :1560025, Beijing
Investigational Site Number :1560021, Beijing
Investigational Site Number :1560018, Shenyang
Investigational Site Number :6420004, Campulung Muscel
Investigational Site Number :6430002, Moscow
Investigational Site Number :6430008, Moscow
Investigational Site Number :1560004, Changchun
Investigational Site Number :6430001, Saint Petersburg
Investigational Site Number :1560003, Shanghai
Investigational Site Number :1560044, Nanjing
Investigational Site Number :1120005, Vitebsk
Investigational Site Number :1560042, Nanjing
Investigational Site Number :1120004, Vitebsk
Investigational Site Number :6430009, Smolensk
Investigational Site Number :1560020, Tianjin
Investigational Site Number :6420002, Timișoara
Investigational Site Number :6430012, Rostov-on-Don
Investigational Site Number :1560035, Fuzhou
Investigational Site Number :6430007, Pyatigorsk
Investigational Site Number :1560019, Chongqing
Investigational Site Number :1560015, Changsha
Investigational Site Number :6420010, Oradea
Investigational Site Number :1560011, Wuhan
Investigational Site Number :6430005, Samara
Investigational Site Number :6430004, Ufa
Investigational Site Number :6420015, Brasov
Investigational Site Number :1560016, Guangzhou
Investigational Site Number :1560028, Guangzhou
Investigational Site Number :1560002, Guangzhou
Investigational Site Number :6420001, Târgu Mureş
Investigational Site Number :6420005, Sibiu
Investigational Site Number :6430011, Nizhny Novgorod
Investigational Site Number :6430003, Nizhny Novgorod
Investigational Site Number :1560005, Chengdu
Investigational Site Number :6430006, Tyumen
Investigational Site Number :6430014, Krasnoyarsk
Investigational Site Number :1560017, Xi'an
Investigational Site Number :1560033, Yinchuan
Investigational Site Number :6420003, Constanța
Axiom Clinical Research of Florida-Site Number:8400001, Tampa
Tufts Medical Center-Site Number:8400072, Boston
Investigational Site Number :1240016, Vancouver
Investigational Site Number :1240003, Ottawa
Investigational Site Number :1240013, Toronto
Investigational Site Number :1240006, Gatineau
Investigational Site Number :1560022, Baotou
Investigational Site Number :1560027, Hohhot
Investigational Site Number :1560014, Shijiazhuang
Investigational Site Number :1560008, Taiyuan
Investigational Site Number :2030003, Teplice
Investigational Site Number :2460003, Helsinki
Investigational Site Number :2760001, Dresden
Investigational Site Number : 3440001, Shatin, NT
Investigational Site Number :7920005, Eskişehir
Investigational Site Number :7920011, Hatay
Investigational Site Number :7920003, Istanbul
Investigational Site Number :7920010, Izmir
Investigational Site Number :3800005, Roma
Investigational Site Number :3800009, Roma
Investigational Site Number :3800013, Roma
Investigational Site Number :3920016, Chiba
Investigational Site Number :3920008, Koriyama-shi
Investigational Site Number :3920012, Tsukuba
Investigational Site Number :3920022, Morioka
Investigational Site Number :3920005, Niigata
Investigational Site Number :3920004, Moriguchi-shi
Investigational Site Number :3920001, Osaka
Investigational Site Number :3920018, Kawagoe-shi
Investigational Site Number :3920014, Bunkyo-ku
Investigational Site Number :3920003, Kodaira-shi
Investigational Site Number :3920010, Ōta-ku
Investigational Site Number :3920013, Shinjuku-ku
Investigational Site Number :3920009, Ube-shi
Investigational Site Number :3920023, Sagamihara-shi
Investigational Site Number :4400004, Šiauliai
Investigational Site Number :4400001, Vilnius
Investigational Site Number :4840002, México
Investigational Site Number :4840001, México
Investigational Site Number :6160008, Plewiska
Investigational Site Number :6160003, Bydgoszcz
Investigational Site Number :6160005, Warsaw
Investigational Site Number :6160006, Warsaw
Investigational Site Number :6160009, Glogow Mlp.
Investigational Site Number :6160002, Katowice
Investigational Site Number :6160004, Katowice
Investigational Site Number :6160001, Lodz
Investigational Site Number :6420008, Bucharest
Investigational Site Number :7240009, Barcelona
Investigational Site Number :7520001, Gothenburg
Investigational Site Number :7520002, Stockholm
Investigational Site Number :8040014, Kyiv
Lead Sponsor
Sanofi
INDUSTRY